Last week, Pfizer reported that a trio of lab experiments suggest that its COVID-19 pill, Paxlovid, will hold up well against the Omicron variant. The antiviral was authorized in December for people at high risk of becoming seriously ill from COVID-19. Unfortunately, despite these promising developments, Paxlovid and other COVID-19 treatments are still in short supply across the country. Half of the 20 million Paxlovid treatment courses purchased by the US aren’t expected to be delivered until June, and the…
